TNFRSF17 and Miyoshi myopathy: In a high tumor burden state in patients with R/R MM undergoing treatment with the anti-BCMA/CD3 bispecific antibody, linvoseltamab, serum sBCMA has been shown to correlate modestly with urine protein (16).